These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8180338)

  • 1. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
    Halbmayer WM; Haushofer A; Schön R; Fischer M
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):51-7. PubMed ID: 8180338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to activated protein C as a basis for venous thrombosis.
    Svensson PJ; Dahlbäck B
    N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
    Dahlbäck B; Carlsson M; Svensson PJ
    Proc Natl Acad Sci U S A; 1993 Feb; 90(3):1004-8. PubMed ID: 8430067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
    Dahlbäck B
    Haemostasis; 1994; 24(2):139-51. PubMed ID: 7959362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
    Cook G; Walker ID; McCall F; Conkie JA; Greer IA
    Br J Haematol; 1994 Aug; 87(4):873-5. PubMed ID: 7986734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway.
    Toulon P; Perez P
    Hematol Oncol Clin North Am; 2000 Apr; 14(2):379-89. PubMed ID: 10806561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
    De Lucia D; Nina P; Papa ML; Belli A; Conte M; Renis V; Di Mauro C; Masi S; Franco A; Schisano G
    J Neurosurg Sci; 1997 Dec; 41(4):373-8. PubMed ID: 9555645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.
    Koster T; Rosendaal FR; de Ronde H; Briët E; Vandenbroucke JP; Bertina RM
    Lancet; 1993 Dec 18-25; 342(8886-8887):1503-6. PubMed ID: 7902898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
    Kraus M; Zander N; Fickenscher K
    Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated protein C resistance phenotype in patients with antiphospholipid antibodies.
    Aznar J; Villa P; España F; Estellés A; Grancha S; Falcó C
    J Lab Clin Med; 1997 Aug; 130(2):202-8. PubMed ID: 9280148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
    Hoagland LE; Triplett DA; Peng F; Barna L
    Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state.
    Sakata T; Kario K; Katayama Y; Matsuyama T; Kato H; Miyata T
    Thromb Res; 1996 May; 82(3):235-44. PubMed ID: 8732627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.
    Sun X; Evatt B; Griffin JH
    Blood; 1994 Jun; 83(11):3120-5. PubMed ID: 8193349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
    Bennet L; Odeberg H
    J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chromogenic assay for activated protein C resistance.
    Váradi K; Moritz B; Lang H; Bauer K; Preston E; Peake I; Rivard GE; Keil B; Schwarz HP
    Br J Haematol; 1995 Aug; 90(4):884-91. PubMed ID: 7669667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a generally applicable tissue factor--dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant.
    Le DT; Griffin JH; Greengard JS; Mujumdar V; Rapaport SI
    Blood; 1995 Apr; 85(7):1704-11. PubMed ID: 7703480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.